Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Nucleic Acids Res ; 44(7): 3095-104, 2016 Apr 20.
Article in English | MEDLINE | ID: mdl-26681690

ABSTRACT

As the formation of ribonucleoprotein complexes is a major mechanism of angiotensin II type 1 receptor (AT1R) regulation, we sought to identify novel AT1R mRNA binding proteins. By affinity purification and mass spectroscopy, we identified TIA-1. This interaction was confirmed by colocalization of AT1R mRNA and TIA-1 by FISH and immunofluorescence microscopy. In immunoprecipitates of endogenous TIA- 1, reverse transcription-PCR amplified AT1R mRNA. TIA-1 has two binding sites within AT1R 3'-UTR. The binding site proximal to the coding region is glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-dependent whereas the distal binding site is not. TIA-1 functions as a part of endoplasmic reticulum (ER) stress response leading to stress granule (SG) formation and translational silencing. We and others have shown that AT1R expression is increased by ER stress-inducing factors. In unstressed cells, TIA-1 binds to AT1R mRNA and decreases AT1R protein expression. Fluorescence microscopy shows that ER stress induced by thapsigargin leads to the transfer of TIA-1 to SGs. In FISH analysis AT1R mRNA remains in the cytoplasm and no longer colocalizes with TIA-1. Thus, release of TIA-1-mediated suppression by ER stress increases AT1R protein expression. In conclusion, AT1R mRNA is regulated by TIA-1 in a ER stress-dependent manner.


Subject(s)
3' Untranslated Regions , Endoplasmic Reticulum Stress , Gene Expression Regulation , Poly(A)-Binding Proteins/metabolism , Receptor, Angiotensin, Type 1/genetics , Binding Sites , Cells, Cultured , Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism , HEK293 Cells , Humans , RNA, Messenger/metabolism , T-Cell Intracellular Antigen-1
2.
Nucleic Acids Res ; 40(12): 5250-61, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22362742

ABSTRACT

Angiotensin II type 1 receptor (AT1R) has a pathophysiological role in hypertension, atherosclerosis and heart failure. Type 2 diabetes is hyperinsulinemic state and a major risk factor for atherosclerosis and hypertension. It is known that hyperinsulinemia upregulates AT1R expression post-transcriptionally by increasing the half-life of AT1R mRNA, but little is known about the mechanism of this effect. In the present study, we first identified AT1R 3'-UTR as a mediator of insulin effect. Using 3'-UTR as a bait, we identified through analysis of insulin-stimulated cell lysates by affinity purification and mass spectrometry HuR as an insulin-regulated AT1R mRNA binding protein. By ribonucleoprotein immunoprecipitation, we found HuR binding to AT1R to be increased by insulin. Overexpression of HuR leads to increased AT1R expression in a 3'-UTR-dependent manner. Both insulin and HuR overexpression stabilize AT1R 3'-UTR and their responsive element within 3'-UTR are located within the same region. Cell fractionation demonstrated that insulin induced HuR translocation from nucleus to cytoplasm increased HuR binding to cytoplasmic AT1R 3'-UTR. Consistent with HuR translocation playing a mechanistic role in HuR effect, a reduction in the cytoplasmic levels of HuR either by silencing of HuR expression or by inhibition of HuR translocation into cytoplasm attenuated insulin response. These results show that HuR translocation to cytoplasm is enhanced by insulin leading to AT1R upregulation through HuR-mediated stabilization of AT1R mRNA.


Subject(s)
ELAV Proteins/metabolism , Gene Expression Regulation , Insulin/pharmacology , RNA Stability , RNA, Messenger/metabolism , Receptor, Angiotensin, Type 1/genetics , 3' Untranslated Regions , Binding Sites , Cells, Cultured , Fatty Acids, Unsaturated/pharmacology , HEK293 Cells , Humans , Kinetics , Protein Transport/drug effects , Receptor, Angiotensin, Type 1/metabolism
3.
Ann Med ; 42(6): 465-74, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20597806

ABSTRACT

AIM: To study if gene alterations affecting renal sodium reabsorption associate with susceptibility to licorice-induced hypertension. METHODS: Finnish subjects (n = 30) with a previously documented incident of licorice-induced hypertension were recruited for the study using a newspaper announcement. Their previous clinical and family histories as well as serum electrolyte levels were examined. DNA samples from all individuals were screened for variants of the genes encoding 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2) and alpha-, beta-, and gamma-subunits of the epithelial sodium channel (ENaC). RESULTS: Upon licorice predisposition, the patients had a mean blood pressure of 201/118 mmHg. Circulating potassium, renin, and aldosterone levels were low. No significant DNA variations were identified in the 11betaHSD2 gene. Four subjects were heterozygous for beta- and gammaENaC variants previously shown to be associated with hypertension. Furthermore, a novel G insertion (2004-2005insG) in the SCNN1A gene encoding the alphaENaC was identified in two subjects. The frequency of these ENaC variants was significantly higher in subjects with licorice-induced hypertension (6/30 i.e. 20%) than in blood donors (11/301 i.e. 3.7%, P = 0.002). CONCLUSIONS: Defects of the 11betaHSD2 gene do not constitute a likely cause for licorice-induced hypertension. Variants of the ENaC subunits may render some individuals sensitive to licorice-induced metabolic alterations and hypertension.


Subject(s)
11-beta-Hydroxysteroid Dehydrogenase Type 2/genetics , Epithelial Sodium Channels/genetics , Glycyrrhiza/adverse effects , Hypertension/chemically induced , Mineralocorticoid Excess Syndrome, Apparent/chemically induced , Adolescent , Adult , Aldosterone/blood , Female , Genetic Variation , Humans , Hypertension/blood , Hypertension/genetics , Kidney/metabolism , Male , Middle Aged , Mineralocorticoid Excess Syndrome, Apparent/blood , Mineralocorticoid Excess Syndrome, Apparent/genetics , Mutagenesis, Insertional , Potassium/blood , Renin/blood , Sodium/metabolism , Young Adult
4.
J Hypertens ; 28(4): 771-9, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20027122

ABSTRACT

OBJECTIVE: In order to get insight into possible genetic determinants of antihypertensive drug action, we analysed the relations between polymorphisms of the genes of the renin-angiotensin-aldosterone system and acute effects of ACE inhibition on blood pressure as well as circulating renin and aldosterone levels in hypertensive patients. METHODS: A total of 315 hypertensive patients referred for problems in drug treatment were given a single 50 mg dose of captopril. Plasma renin and aldosterone were measured before and 60 min after the drug administration. Four DNA variants, including angiotensin type I receptor (AGTR1) 1166 A/C, angiotensin-converting enzyme (ACE) I/D, angiotensinogen (AGT) M235T and AGT -217 G/A, were genotyped in the patients and normotensive men (n = 175). A replication study on the relation between AGTR1 1166 A/C and plasma renin and aldosterone levels was carried out in the 244 hypertensive men of the pharmacogenetic GENRES Study. RESULTS: Referred hypertensive patients with the AGTR1 CC genotype had higher aldosterone at baseline (P = 0.02) and after 60 min of captopril administration (P = 0.01) compared with the AA genotype. Replicate analysis in the GENRES patients showed a similar trend. When the two studies were combined (315 and 244 patients, respectively), plasma aldosterone level (P = 0.007) as well as aldosterone/renin ratio (P = 0.04) were significantly higher in the CC genotype (n = 13) than in the AA genotype (n = 370). Transfection studies in cultured HEK293 cells indicated that the 1166C allele was associated with higher mRNA levels than the 1166A allele. CONCLUSION: The AGTR1 1166C allele when present in homozygous form may be associated with a form of essential hypertension characterized by high plasma aldosterone and low plasma renin levels, possibly due to increased AGTR1 mRNA levels and augmented angiotensin II action.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Genetic Variation , Hypertension/drug therapy , Renin-Angiotensin System/genetics , Adult , Aldosterone/blood , Alleles , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Angiotensinogen/genetics , Angiotensinogen/pharmacology , Angiotensinogen/therapeutic use , Antihypertensive Agents/pharmacology , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Blood Pressure/genetics , Captopril/pharmacology , Captopril/therapeutic use , Cohort Studies , Female , Gene Frequency , Genotype , Humans , Hypertension/genetics , Male , Middle Aged , Polymorphism, Genetic , Receptors, Angiotensin/genetics , Receptors, Angiotensin/therapeutic use , Reference Values , Renin/blood , Renin-Angiotensin System/drug effects
5.
Nucleic Acids Res ; 37(7): 2346-58, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19246543

ABSTRACT

Regulation of angiotensin II type 1 receptor (AT1R) has a pathophysiological role in hypertension, atherosclerosis and heart failure. We started from an observation that the 3'-untranslated region (3'-UTR) of AT1R mRNA suppressed AT1R translation. Using affinity purification for the separation of 3'-UTR-binding proteins and mass spectrometry for their identification, we describe glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an AT1R 3'-UTR-binding protein. RNA electrophoretic mobility shift analysis with purified GAPDH further demonstrated a direct interaction with the 3'-UTR while GAPDH immunoprecipitation confirmed this interaction with endogenous AT1R mRNA. GAPDH-binding site was mapped to 1-100 of 3'-UTR. GAPDH-bound target mRNAs were identified by expression array hybridization. Analysis of secondary structures shared among GAPDH targets led to the identification of a RNA motif rich in adenines and uracils. Silencing of GAPDH increased the expression of both endogenous and transfected AT1R. Similarly, a decrease in GAPDH expression by H(2)O(2) led to an increased level of AT1R expression. Consistent with GAPDH having a central role in H(2)O(2)-mediated AT1R regulation, both the deletion of GAPDH-binding site and GAPDH overexpression attenuated the effect of H(2)O(2) on AT1R mRNA. Taken together, GAPDH is a translational suppressor of AT1R and mediates the effect of H(2)O(2) on AT1R mRNA.


Subject(s)
3' Untranslated Regions/metabolism , Gene Expression Regulation , Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism , Protein Biosynthesis , Receptor, Angiotensin, Type 1/genetics , Base Sequence , Cell Line , Glyceraldehyde-3-Phosphate Dehydrogenases/antagonists & inhibitors , Glyceraldehyde-3-Phosphate Dehydrogenases/genetics , Humans , Hydrogen Peroxide/pharmacology , Molecular Sequence Data , RNA Interference , RNA, Messenger/chemistry , RNA, Messenger/metabolism , RNA-Binding Proteins/metabolism , Receptor, Angiotensin, Type 1/metabolism
6.
Nucleic Acids Res ; 36(13): 4474-87, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18603592

ABSTRACT

p100 protein (SND1, Tudor-SN) is a multifunctional protein that functions as a co-activator for several transcription factors, has a role in mRNA processing and participates in RNAi-induced silencing complex (RISC) with yet unknown function. In this study we identified a novel function for p100 as a regulator of angiotensin II type 1 receptor (AT1R) expression. The binding of p100 to AT1R 3'-untranslated region (3'-UTR) via staphylococcal nuclease-like (SN-like) domains increased receptor expression by decreasing the rate of mRNA decay and enhancing its translation. Overexpression of p100 increased AT1R expression, whereas decrease in p100 binding to 3'-UTR either by p100 silencing or by the deletion of p100 binding site downregulated receptor expression. The effect of p100 through AT1R 3'-UTR was independent of Argonaute2 (Ago2), a known p100 partner, and was thus RISC-independent. Nucleotides 118 to 120 of the AT1R 3'-UTR were found to be critical for the binding of p100 to 3'-UTR. In summary, p100 is a multifunctional regulator of gene expression that regulates transcription, mRNA maturation, and as described in this article, also mRNA stability and translation.


Subject(s)
3' Untranslated Regions/metabolism , Nuclear Proteins/metabolism , RNA Stability , RNA, Messenger/metabolism , Receptor, Angiotensin, Type 1/genetics , 3' Untranslated Regions/chemistry , Animals , Argonaute Proteins , Binding Sites , Cell Line , Down-Regulation , Electrophoretic Mobility Shift Assay , Endonucleases , Eukaryotic Initiation Factor-2/metabolism , Genes, Reporter , Humans , Immunoprecipitation , Luciferases/analysis , Luciferases/genetics , MicroRNAs/metabolism , Nuclear Proteins/chemistry , Protein Biosynthesis , Protein Structure, Tertiary , RNA-Induced Silencing Complex/metabolism , Receptor, Angiotensin, Type 1/biosynthesis
7.
Cytokine Growth Factor Rev ; 15(6): 435-55, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15561601

ABSTRACT

Signal transducers and activators of transcription (Stats) comprise a family of seven transcription factors that are activated by a variety of cytokines, hormones and growth factors. Stats are activated through tyrosine phosphorylation, mainly by Jak kinases, that lead to their dimerization, nuclear translocation and regulation of target gene expression. Stat5 was originally identified as a transcription factor that regulates the beta-casein gene in response to prolactin (PRL), but Stat5 is activated also by several other cytokines and growth factors. The molecular mechanisms that underlie Stat5-mediated transcription involve interactions and cooperation with sequence specific transcription factors and transcriptional coregulators. Our studies identified p100 protein as a coactivator for Stat5, and suggest the existence of a positive regulatory loop in PRL-induced transcription, where PRL stabilizes p100 protein, which in turn can cooperate with Stat5 in transcriptional activation. Suppressors of cytokine signaling (SOCS) proteins are important negative regulators of Stats. A target gene for Stat5, the serine/threonine kinase Pim-1, was found to cooperate with SOCS-1 and SOCS-3 to inhibit Stat5 activity suggesting that Pim-1 together with SOCS-1 and SOCS-3 are components of a negative feedback mechanism that allows Stat5 to regulate its own activation.


Subject(s)
DNA-Binding Proteins/metabolism , Milk Proteins/metabolism , Signal Transduction/physiology , Trans-Activators/metabolism , Transcription, Genetic , Animals , Cytokines/metabolism , DNA-Binding Proteins/chemistry , DNA-Binding Proteins/genetics , GTP-Binding Proteins/metabolism , Gene Expression Regulation , Growth Substances/metabolism , Milk Proteins/chemistry , Milk Proteins/genetics , Nuclear Proteins/metabolism , Protein Conformation , Protein Serine-Threonine Kinases/metabolism , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-pim-1 , Receptors, Cell Surface/metabolism , STAT5 Transcription Factor , Trans-Activators/chemistry , Trans-Activators/genetics
8.
Blood ; 103(10): 3744-50, 2004 May 15.
Article in English | MEDLINE | ID: mdl-14764533

ABSTRACT

Signal transducer and activator of transcription 5 (STAT5) plays a critical role in cytokine-induced survival of hematopoietic cells. One of the STAT5 target genes is pim-1, which encodes an oncogenic serine/threonine kinase. Here we demonstrate that Pim-1 inhibits STAT5-dependent transcription in cells responsive to interleukin-3, prolactin, or erythropoietin. Ectopic expression of Pim-1 in cytokine-dependent FDCP1 myeloid cells results in reduced tyrosine phosphorylation and DNA binding of STAT5, indicating that Pim-1 interferes already with the initial steps of STAT5 activation. However, the Pim-1 kinase does not directly phosphorylate or bind to STAT5. By contrast, Pim-1 interacts with suppressor of cytokine signaling 1 (SOCS1) and SOCS3 and potentiates their inhibitory effects on STAT5, most likely via phosphorylation-mediated stabilization of the SOCS proteins. Thus, both Pim and SOCS family proteins may be components of a negative feedback mechanism that allows STAT5 to attenuate its own activity.


Subject(s)
Carrier Proteins/metabolism , DNA-Binding Proteins/antagonists & inhibitors , Milk Proteins , Protein Serine-Threonine Kinases/physiology , Proto-Oncogene Proteins/physiology , Repressor Proteins/metabolism , Trans-Activators/antagonists & inhibitors , Transcription Factors/metabolism , Transcription, Genetic , Animals , Carrier Proteins/genetics , Cell Line , DNA-Binding Proteins/physiology , Feedback, Physiological , Mice , Myeloid Cells/cytology , Myeloid Cells/metabolism , Phosphorylation , Protein Binding , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-pim-1 , Repressor Proteins/genetics , STAT5 Transcription Factor , Suppressor of Cytokine Signaling 1 Protein , Suppressor of Cytokine Signaling 3 Protein , Suppressor of Cytokine Signaling Proteins , Trans-Activators/physiology , Transcription Factors/genetics , Transfection
9.
Mol Endocrinol ; 17(9): 1805-14, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12819296

ABSTRACT

Signal transducer and activator of transcription 5 (Stat5) plays a critical role in prolactin (PRL)-induced transcription of several milk protein genes. Stat5-mediated gene regulation is modulated by cooperation of Stat5 with cell type- and promoter-specific transcription factors as well as by interaction with transcriptional coregulators. Recently, the expression of a tudor and staphylococcal nuclease-like domains containing protein p100 was found to be increased in mammary epithelial cells during lactation in response to lactogenic hormones. p100 was initially identified as a transcriptional coactivator of the Epstein-Barr virus nuclear antigen 2. In this study we investigated the potential role of p100 in PRL-induced Stat5-mediated transcriptional activation. PRL stimulation increased the p100 protein levels in HC11 mouse mammary epithelial cells. p100 did not affect the early activation events of Stat5, but p100 enhanced the Stat5-dependent transcriptional activation in HC11 cells. p100 associated with Stat5 both in vivo and in vitro, and the interaction was mediated by both the tudor and staphylococcal nuclease-like domains of p100. Together these results suggest that p100 functions as a transcriptional coactivator for Stat5-dependent gene regulation and the existence of a positive regulatory loop in PRL-induced transcription, in which PRL stabilizes p100 protein, which in turn can cooperate with Stat5 in transcriptional activation.


Subject(s)
DNA-Binding Proteins/genetics , Milk Proteins , Nuclear Proteins/metabolism , Trans-Activators/genetics , Animals , COS Cells , Chlorocebus aethiops , DNA-Binding Proteins/metabolism , Endonucleases , Protein Structure, Tertiary , STAT5 Transcription Factor , Signal Transduction/physiology , Trans-Activators/metabolism
10.
Eur J Pharmacol ; 452(1): 87-96, 2002 Sep 27.
Article in English | MEDLINE | ID: mdl-12323389

ABSTRACT

The aim of the present study was to evaluate the vascular effects of genistein in a short-term study. The ovariectomized spontaneously hypertensive rats (SHR) were divided into four groups (n = 8 in each), which received the following subcutaneous treatments either for 2 days or for 2 weeks: (1) solvent control (96% dimethylsulphoxide (DMSO) 1 ml/kg), (2) estradiol-17beta (25 microg/kg), (3) genistein (2.5 mg/kg; low-dose), and (4) genistein (25 mg/kg; high-dose). The renal arterial rings were studied using organ bath system. The renal artery contractions were attenuated by the 2-day low-dose genistein treatment as follows: angiotensin II (46%), noradrenaline (42%) KCl (36%), and endothelin-1 (34%). Only the angiotensin II-induced contractions were reduced by the 2-week treatment with estradiol-17beta (38%) and with the low-dose of genistein (31%). The 2-day genistein treatment reduced tyrosine phosphorylation, while the other treatments or treatment times had no effect. The 2-day low-dose genistein treatment had no estrogenic effect on the uterine morphology. The mechanism for attenuated contractility in the renal arteries after the 2-day low-dose genistein treatment is independent of the estrogenic effect of genistein, but is due to the tyrosine kinase inhibitory property of genistein.


Subject(s)
Arteries/physiopathology , Enzyme Inhibitors/pharmacology , Genistein/pharmacology , Hypertension/physiopathology , Muscle, Smooth, Vascular/physiopathology , Ovariectomy , Protein-Tyrosine Kinases/antagonists & inhibitors , Animals , Arteries/drug effects , Blood Pressure/drug effects , Body Weight/drug effects , Creatinine/urine , Eating/drug effects , Electrolytes/urine , Estradiol/pharmacology , Female , Hypertension/genetics , Muscle Contraction/drug effects , Muscle, Smooth, Vascular/drug effects , Nitric Oxide/metabolism , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type III , Organ Size/drug effects , Phosphorylation , Rats , Rats, Inbred SHR , Renal Circulation/drug effects , Tyrosine/metabolism , Uterus/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...